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Neurosteroids are synthesized in the brain and modulate brain excitability. There is increasing evidence of their
sedative, anesthetic and antiseizure properties, as well as their influence on mood. Currently neurosteroids are
classified as pregnane neurosteroids (allopregnanolone and allotetrahydrodeoxycorticosterone), androstane
neurosteroids (androstanediol and etiocholanone) or sulfated neurosteroids (pregnenolone sulfate and
dehydroepiandrosterone sulfate). Both preclinical and clinical findings indicate that progesterone derivative
neurosteroids such as allopregnanolone and allotetrahydrodeoxycorticosterone play a role in mood disorders.
Clozapine and olanzapine, which were shown to be effective in stabilizing bipolar disorder, elevate pregnenolone
levels in rat hippocampus, cerebral cortex, and serum. In lithium-treated mice, the blood levels of allopregnanolone
and pregnenolone were elevated compared to control levels. Women diagnosed with bipolar disorder typically
show symptomatic exacerbation in relation to the menstrual cycle, and show vulnerability to the onset or
recurrence of mood disorders immediately after giving birth, when the levels of neurosteroid derivatives of
progesterone drop. Whereas in women who had recovered from bipolar disorder, the plasma concentration of
allopregnanolone was elevated compared to either healthy controls or women with major depressive disorder
during the premenstrual period. During depressive episodes, blood level of allopregnanolone is low. Treatment
with fluoxetine tends to stabilize the levels of neurosteroids in depression. These findings converge to suggest that
these steroids have significant mood-stabilizing effect. This hypothesis is consistent with the observation that a
number of anticonvulsants are effective therapies for bipolar disorder, a finding also consistent with the antiseizure
properties of neurosteroids. Further exploration of action of neuroactive steroids is likely to open new frontiers in
the investigation of the etiology and treatment of mood disorders, particularly bipolar disorders.Introduction
Pharmacotherapy of severe mental disorders has not
changed significantly since the introduction of anti-
psychotic compounds in the 1950s. The current classes
of drugs available to treat schizophrenia, bipolar disorder
and major depression involve essentially the same
mechanisms of action and the same neurobiological tar-
get [1]. Arguably the most important advance in the
pharmacotherapy of severe mental disorders in the last
fifty years was the substitution of barbiturates with the
clinically safer benzodiazepines and the introduction of
the theory-driven selective serotonin reuptake inhibitors
for the treatment of depression. Nevertheless, the* Correspondence: mgcarta@tiscali.it
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reproduction in any medium, provided the oreffectiveness of currently available drugs is poor, both
because only selected subgroups of patients were found
to be good responders to the prescribed drugs [2,3] and
because compliance to treatment is generally low be-
cause of side effects and poor insight on the necessity of
a severe mental disorder needing long-term therapy
[4,5].
The development of new therapeutic targets in the
treatment of severe mental disorders is hampered by the
lack of external, biological markers of the nosographic
phenotypes [6,7], the scarce knowledge of the neurobio-
logical and genetic substrates of the categorically defined
disorders [8] and the difficulties in devising valid and re-
liable animal models, which often lack predictive validity
in the prediction of drug actions in humans [9]. There-
fore, serendipity is as likely to guide discovery now as it
was in the past. However, it is always possible to help
serendipity-assisted drug discovery by looking at thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Gender issues in the epidemiology of severe mental
disorders
There is robust epidemiological evidence that patients
diagnosed with schizophrenia and mood disorders show
gender differences in the onset, course and outcome of
their disorders. Since the German ABC study (Age, Be-
ginning, Course) on schizophrenia, it is well known that
females have two peaks in the onset of schizophrenia,
contrary to males [10,11]. Recent systematic reviews and
meta-analyses confirmed that males are over-represented
in the samples of patients diagnosed with first-episode
schizophrenia. They are generally younger at first con-
tact, and tend to have a poorer outcome compared to
females [12-15]. To account for these findings, it was
suggested that estrogens may have modulated dopami-
nergic hyperactivity in females, thus leading to a gradual
progression of the course of the disorder and a later
onset of frank psychosis [11,16,17]. This hypothesis was
compatible with the two incidence peaks in female psych-
osis onset; one in the early 20s, also common among
males, albeit slightly later, and another after 40 years,
possibly related to menopause [10,18].
Mood disorders show a different picture, with women
having an increased risk for developing major depression
compared to males [19]. The risk of hypomania, rapid
cycling and mixed episodes is also higher among women
than men [20]. However, men and women suffer the
same incidence of bipolar disorder and essentially with
the same outcome [19,20]. If steroids have a role in
schizophrenia related psychoses, this role is reversed in
affective psychoses. The discovery that the brain can
synthesize neuroactive steroids and that their action is
widespread on neuronal cells opened up an entirely new
area in the investigation on rge effects of steroids on be-
havior [21,22].
Sex steroids and the brain
Peripherally, steroids are produced mainly by the adrenal
cortex and the gonads and are regulated by the
hypothalamic-pituitary-adrenal axis and the hypothal-
amic pituitary-adrenal gonadal axis through negative
feedback. The ovarian steroids regulate neuroendocrine,
endocrine and behavioral functions through a number of
cellular mechanisms. Typically, both estrogen and pro-
gesterone induce a relatively long-term action on neu-
rons by activating a number of intracellular receptors
that modulate the transcription and protein synthesis.
The steroid hormones play an important role in both
the central and peripheral nervous systems; they act dur-
ing development, growth, maturation and cellular differ-
entiation. The progesterone receptor and the nuclearhormone family of intracellular estrogen receptors, alpha
and beta (encoded by two separate genes), are dimeric
molecules that regulate transcription of target genes in
the nuclei [23,24]. These receptors have a C-terminal
and an N-terminal zinc-finger domains that mediate
binding of the receptors to target DNA sequences. In
the absence of the binding hormone, the C-terminal of
the receptors inhibits transcription. The binding of the
hormone induces a change in the dimeric structure of
the receptors, and this removes the inhibitory action.
Estrogens also bind to a G-protein coupled receptor,
which as a transmembrane G-protein mediates estrogen-
dependent kinase activation [25].
Both estradiol and progesterone receptors are found in
the Central Nervous System (CNS) [26]. Progesterone is
rapidly absorbed and metabolized in the cerebral cortex
[27]. Because of their lipophilic nature, the steroids pro-
duced by the endocrine glands pass freely through the
blood–brain barrier. The concentration of estradiol and
progesterone in the brain closely follows peripheral con-
centrations. The brain is one of the targets of steroid
hormones [28,29]. In general, estradiol induces excita-
tory actions while progesterone induces inhibitory
actions on the CNS. The ovarian steroids modulate
many functions of the CNS, such as memory and learn-
ing [30], movement [31], and the perception of pain
[32]. The ovarian steroids regulate neuroendocrine,
endocrine and behavioral functions through a number of
cellular mechanisms.
Neurosteroids and their role in the brain
Baulieu and co-workers were the first to observe that
the brain concentrations of dehydroepiandrosterone sul-
fate were partially independent from adrenal and gonad
secretion [33]. Subsequently, the demonstration of de
novo synthesis of active steroids in the brain leads to the
conceptualization of these brain-acting steroids as neu-
rosteroids [21]; neurosteroids are synthesized from cir-
culating steroid hormones, which serve as precursors of
active neurosteroids. Currently, neurosteroids are
defined as those that are synthesized in the brain. Neu-
roactive steroids refer to steroids that, independent of
their origin, are capable of modifying neural activities.
Currently neuroactive steroids are classified as preg-
nane neurosteroids (allopregnanolone and allotetrahydro-
deoxycorticosterone or THDOC), androstane neurosteroids
(androstanediol and etiocholanone) or sulfated neuroster-
oids (pregnenolone sulfate or PS and dehydroepiandroster-
one sulfate or DHEAS).
Several enzymes are involved in the synthesis of neu-
roactive steroids: neuroactive steroids such as allopreg-
nanolone, THDOC, and androstanediol are produced by
5α-reductase and 3α-hydroxysteroid oxidoreductase
(3α-HSOR), which act by reducing the parent steroid in
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5α-reductase and the 3α-HSOR were identified in both
neural and glial cells [35,36] and found in neocortex and
subcortical white matter and in hippocampal tissues
[37,38]. In particular, a cytochrome P450 cholesterol
side-chain cleavage enzyme (CYP450scc) was identified,
and was proven to have the ability to convert choles-
terol to pregnenolone, which is a precursor for the syn-
thesis of neurosteroids [39]. Another enzyme necessary
for the conversion of pregnenolone to progesterone, 3β-
hykdroxysteroid dehydrogenase, was found in the brain
[40]; further details on the synthesis of neuroactive ster-
oids in [41].
In the brain de novo synthesis of neurosteroids occurs
in the cortex, the hippocampus and the amygdala,
mainly in glutamatergic neurons [27]. Regulatory
mechanisms involved in this de novo synthesis are still
unclear [42].
Non-genomic actions of neurosteroids
There is evidence that neurosteroids do not produce
most of their effects through an interaction with the
steroid hormone receptors that regulate gene transcrip-
tion. But, neurosteroids can regulate gene expression via
the progesterone receptor. But this occurs only after
conversion of the neurosteroids to typical steroids. The
induction of DNA binding and transcriptional activation
of the progesterone receptor requires intracellular oxida-
tion of the neuroactive steroids into progesterone recep-
tor active 5 alpha-pregnane steroids [43]. Most effects of
neurosteroids occur by interaction with neuronal mem-
brane receptors and ion channels [44]. The post-synaptic
GABAA receptor is the most important site where neu-
roactive steroids act as positive or negative regulators
[19], which is consistent with their chemical structure.
Neurosteroids involvement in the regulation of
GABAergic transmission
The GABAA receptor is the main target of action of
neuroactive steroids. GABAA receptors are heteropenta-
meric GABA-gated chloride channels: they are involved
in fast inhibitory neurotransmission. The GABAA recep-
tor, distributed in large quantity throughout the CNS, is
a macromolecular complex consisting of five subunits,
of which many homologs have been identified (alpha1-6,
beta1-3, gamma1-3, delta, epsilon, theta, pi and rho1-3).
In each receptor, these five subunits are assembled
from among 19 different subunit isoforms [45]. Compos-
ition of the five subunits determines the functional
and pharmacological properties of GABAA receptors.
The best-known and most widely distributed form in
the CNS consists of two alphas, two betas, and a third
subunit, which together constitute the chloride ion
channel. Different assemblages of the five subunitsdetermine differences in the functioning of the channel
and differences in the response to the drugs acting on
the receptor [46].
Site-specific binding of the GABAA receptor, in sub-
unit beta, determines the opening of the ion channel
and chloride influx. The increase in negative charge
leads to a hyperpolarization of the membrane, making it
less susceptible to excitation [46]. The activation of
GABAA receptors prevents a potential short circuit in
the depolarization induced by excitatory neurotransmit-
ters. The activity of these receptors is also modulated by
a number of agents including benzodiazepines, barbitu-
rates, some anesthetics and ethanol [47].
The neurosteroids allopregnanolone and THDOC are
strong positive allosteric modulators of the GABAA
receptors [48], but at a different site than the site bound
by the barbiturates and the benzodiazepines [48]. The
neuroactive steroids increase the flow of chloride ions
from GABAA receptors, by increasing both the fre-
quency and duration of the opening of the ion channel
[49]. Due to the increased probability of opening of the
chloride channel of the GABAA receptor, neuroactive
steroids increase a massive influx of the ion and potenti-
ate inhibitory GABAergic transmission [49].
In vivo, the basal plasma concentration of neuroactive
steroids seems sufficient to significantly potentiate the
function of the GABAA receptor [50]. Neuroactive ster-
oids can also modulate recombination of various subu-
nits of the GABAA receptor [51]. This recombination
can change the action of substances such as alcohol and
drugs on the GABAA receptor: the action of these sub-
stances on the GABAA receptor depends on receptor as-
sembly [52].
The steroid sulfates are non-competitive antagonists
of the GABAA receptors, acting on different sites
from those bound by allopregnanolone and THDOC
[53]. The negative modulatory action of neuroactive
steroids is produced through a reduction in channel
opening, but the precise mechanism of this blocking
is still not well understood [54]. The neuroactive ste-
roid sulfates also modulate GABAergic transmission
through a poorly known presynaptic mechanism
[55]. Given the abundance of pregnenolone sulfate (PS)
and dehydroepiandrosterone-3-sulfate (DHEAS) in the
brain, it seems likely that they can act as endogenous
neuromodulators [56]; this in conjunction with neuro-
steroids such as allopregnanolone and THDOC, which
are strong positive allosteric modulators of the GABAA
receptors.
Studies carried out in amphibians showed that GABA,
through its GABAA receptors, is involved in the control
of neurosteroidogenesis, with GABA inhibiting it [56].
Therefore, a short, regulatory loop linking neuroactive
steroids’ effects to GABA actions might exist.
Carta et al. Behavioral and Brain Functions 2012, 8:61 Page 4 of 8
http://www.behavioralandbrainfunctions.com/content/8/1/61The study of progesterone derivatives in epilepsy and
mood disorders
The role of allopregnanolone and THDOC has been
studied in a number of pathologies including epilepsy
[57], premenstrual syndrome [57], anxiety [58] and mood
disorders [59,60].
These steroids show a protective action in epilepsy
and elevate the threshold of convulsive crisis, particu-
larly in so-called catamenial epilepsy, in which the crises
worsen during the premenstrual phase. Indeed, clinical
studies have demonstrated the potential therapeutic util-
ity of synthetic analogs of allopregnanolone in the treat-
ment of catamenial epilepsy [57]. The reduction in the
concentration of progesterone derivatives in the luteinizing
phase of the menstrual cycle impacts on the clinical
manifestations of premenstrual syndrome and premen-
strual dysphoric disorder (PMDD) [61], and it is consist-
ent with these findings. PMDD is associated with mood
disorders [62], and during depressive episodes, the level
of allopregnanolone is low [63]. Conversely, the plasma
concentration of allopregnanolone is elevated in patients
with panic disorder [64], or following a panic attack
[65].
The treatment with fluoxetine stabilizes the level of
neurosteroids in depression and panic, and it has been
hypothesized that at least part of the therapeutic effect
of selective serotonin re-uptake inhibitors (SSRIs) could
be through their influence on neurosteroids [66,67]. Re-
cent findings indicate that neurosteroids such as dehy-
droepiandrosterone, pregnenolone and their sulfate
esters (progesterone and allopregnanolone) affect neur-
onal survival, neurite outgrowth and neurogenesis [68].
Re-establishment of neuronal plasticity (dendritic re-
modeling and synaptic contacts) in the hippocampus
may be important for the pathogenesis and amelioration
of depressive symptoms [69]. Neurosteroids might have
a role in resetting neurogenesis in some areas of the
brain, and specifically in the hippocampus during recov-
ery from depressive episodes.
A role for progesterone-derived neurosteroids in
bipolar disorders?
In women with bipolar disorders during euthymia,
plasma concentration of the progesterone derivative allo-
pregnanolone is elevated in the premenstrual period
compared to healthy controls and women with major
depressive disorder [70]. This finding is independent
from pharmacological therapy status and not related to
anxiety or eating disorders. It was speculated that these
neurosteroids would act as endogenous mood stabilizers.
Indeed, during episodes of depression levels of allopreg-
nanolone were reported to be low [63], while the plasma
concentration is elevated in patients with panic disorder
[64], or after the induction of a panic attack [65]. Panicattack anxiety disorder is highly comorbid with type II
bipolar disorder, and it has been suggested that the clin-
ical manifestations of the panic attack is an expression
of hyperthymia, specifically the “anxious hyperthymia”;
this is a possible personality pre-morbid trait in panic
disorder [71]. Both major depression and panic disorder
are strongly bound to bipolar disorder, in terms of
comorbidity [72], familiarity [73] and in a purported syn-
dromic continuum with major depressive disturbance
[74,75].
Irritable mood is another component of mood eleva-
tion in bipolar disorder. Anabolic/androgenic steroids
increase sex drive and mental acuity. If abused, such
steroids can cause irritability and impulsive aggression
[76]. Social isolation in male mice and long-term treat-
ment with anabolic steroids in female mice induces
strong aggressive behavior towards intruders. In both
sexes, a decrease of brain allopregnanolone is associated
with such induced aggressive behavior [77]. Conversely,
progesterone and its metabolite allopregnanolone have
been implicated in suppressing irritability. Johannson
et al. [78] conducted a study to determine whether or
not a history of manic/hypomanic irritability is asso-
ciated with low serum progesterone levels; they further
tested whether single nucleotide polymorphisms (SNPs)
in genes coding for steroidogenetic enzymes were
coupled to previous manic irritability and/or with serum
progesterone concentrations. They found that in males
with bipolar disorders, progesterone concentrations were
lower in those who had shown manic/hypomanic irrit-
ability compared with nonirritable patients. Specific
SNPs were associated with manic/hypomanic irritability.
Thus low progesterone levels and a cystine to serine
change at position 145 in AKR1C4 gene were associated
with manic/hypomanic irritability in males. Given that
the enzyme AKR1C4 has both dehydrogenating and re-
ductive activities in the steroidogenetic pathway, a mis-
sense variation in the gene may predispose to manic/
hypomanic irritability by altering the relationship be-
tween progesterone and allopregnanolone.
More recently, the same group [79] found that in bi-
polar women, SNPs in AKR1C4 reduced the likelihood
of exhibiting paranoid ideation during manic episodes by
about 60%. Hence, gene variants in the steroidogenetic
pathway and steroids concentration differences may be
involved in the susceptibility to paranoia during mood
elevation. Hardoy et al. [59] attempted to verify if differ-
ences in neurohormonal blood levels may be directly
linked to some syndromal lifetime clusters (dimensions)
using the Structural Clinical Interview for Mood
Spectrum-Self Reported (SCI-MOODS-SR) [80] ques-
tionnaire of the mood spectrum independent of diagno-
sis in females with a lifetime diagnosis of major mood
disorder (Bipolar Disorder, Major Depressive Disorder).
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luteal phase of their menstrual cycle and in a condition
of clinical well-being. The analysis of the main compo-
nents of the syndromal cluster evidenced the presence
of 3 components identified by analysis of main compo-
nents with Varimax rotation and Kaiser's normalization:
1) mania, 2) depression with mixed symptoms of agita-
tion 3) irritable/elated cognition and suicidal ideas.
Levels of allopregnanolone and progesterone were not
associated with the mixed-depressive or purely manic
syndromes, but rather with the symptom dimension
characterized by irritable/elated cognition associated
with suicidal thoughts. These results indicated that
patients in euthymic, stabilized condition but with a his-
tory of irritable/elated symptoms mixed with suicide
ideation had, at the evaluation time, higher blood
levels of progesterone and derivates. These results are
in apparent contradiction with the above discussed
Johansson et al. [78] findings of low progesterone blood
levels in bipolar patients of mixed states. However,
taking into account the possibility that the steroids
would act as endogenous mood stabilizers, this data can
also be interpreted as patients with more severe mixed
states need higher steroid levels to reach recovery com-
pared to patients without past mixed symptoms. On the
other hand, the hypothesis that steroids may be an en-
dogenous mood stabilizer is supported by the evidence
from case reports of recovery from post partum refrac-
tory mania [81]. Thus, progesterone and derivates may
be particularly relevant on mixed – aggressive compo-
nent of bipolar symtomathology.
It can also be hypothesized that a dysregulated system
in patients with bipolar disorder would cause low levels of
neuroactive steroids during depression and mixed states.
Thus, drugs able to correct the malfunctioning of systems
based on neurosteroids could improve clinical status in
patients with bipolar disorder spectrum conditions.
Fluoxetine, which is effective in panic attack and
major depression, also affect the levels of neurosteroids
[66,67]. A role for neurosteroids in bipolar disorder is
also consistent with the observation that a number of
anticonvulsants (including valproate, lamotrigine and
carbamazepine) are effective in bipolar disorder [82,83],
an effect that could be partially due to action on neu-
rosteroids. Therefore endogenous neuroactive steroids
with anticonvulsant properties may play a role in the
pathogenesis of bipolar disorders. Lithium is another
effective therapeutic agent in bipolar disorder. Precli-
nical evidence suggests that lithium might induce its
action via an effect on neurosteroids. The levels of
allopregnanolone and pregnenolone were found signifi-
cantly elevated in lithium-treated mice. Pregnenolone
levels also tend to be higher following lithium treatment
in humans [84].Even the two atypical antipsychotics clozapine and
olanzapine, effective against the manic phase of bipolar
disorder [85,86], were proven to modify the levels of
neurosteroids in animal studies. Clozapine markedly ele-
vates pregnenolone in rat hippocampus, cerebral cortex,
and serum; hippocampal levels were strongly correlated
with serum levels. Olanzapine elevates pregnenolone
levels, too, but to a lesser extent than clozapine [87,88].
Olanzapine, fluoxetine or their combination increased
hippocampal pregnenolone and serum deoxycorticoster-
one in both higher- and lower-dose experiments, and
elevated hippocampal allopregnanolone in higher-doses
[89]. Since olanzapine and fluoxetine combination have
clinical utility particularly in bipolar depression [90,91],
and decrease of pregnenolone levels have been linked to
depression, it is possible that olanzapine- and fluoxetine-
induced pregnenolone elevations may contribute to the
antidepressant actions of these agents in bipolar
depression.
Effects of neurosteroids on mood fluctuation might ex-
tend across the bipolar disorder spectrum. Women of
reproductive age with mental disorders may experience
a fluctuating course of illness over the menstrual cycle.
Some data suggest that for a subset of women there is a
relationship between phases of the menstrual cycle and
increased vulnerability for an exacerbation of ongoing
mood disorders [22] (the so-called “catamenial mood
disorder” [70]). A critical period is the one immediately
following the birth of a child, when the level of proges-
terone neurosteroid derivatives drop; the post-natal
period is linked to an increased vulnerability to the onset
or recurrence of mood disorders [92].
Neuroactive steroids and GABAergic drugs in bipolar
disorders
Recent research data from some GABAergic com-
pounds, including gabapentin [93,94], tiagabine [95],
topiramate [96], have produced disappointing and con-
flicting results as far as their effectiveness in bipolar dis-
order is concerned. Preliminary evidence of their
effectiveness in patients diagnosed with bipolar disorder
was not confirmed by subsequent randomized, placebo-
controlled studies [97-99].
Most antiepileptic compounds exert a direct or indir-
ect GABA-mediated inhibitory action [100]. However,
the impact of the neuroactive steroids on the structure
of the GABAA receptor is a factor that has not been
adequately examined in the investigation of the phar-
macological action of putatively GABAergic drugs.
Indeed, patients with bipolar disorder often abuse
alcohol or drugs such as benzodiazepines [101], which
can induce changes in the heteropentameric structure
of the GABAA receptor, changes that may alter the
subsequent action of drugs targeting the GABAA
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or midazolam were found to promote neurosteroid syn-
thesis [102-104]. Moreover, if neurosteroids really are
involved in the etiology of bipolar disorder and their
levels fluctuate during the different phases of the dis-
order, the influence of neurosteroids on the GABAA
receptors also will fluctuate. This will further modify the
responsiveness to GABAergic compounds. Effectiveness
of potentially antimanic GABAergic drugs would depend
of the status of the GABAA receptors on which they
exert their action, and on levels of neurosteroids acting
on the GABAA receptors. Overall, the chance of finding
a therapeutic effectiveness of GABAergic compounds
will be a function of: a) inter-individual differences in
neurosteroids synthesis, secretion and action at the tar-
get receptor; b) the conformation of the GABAA recep-
tor as a function of alcohol and/or preceding treatment
with drugs acting on it; the phase of the disorder,
whether depressive or excitatory. Gender differences in
neurosteroids functioning also would have an impact on
the effectiveness of GABAergic compounds in bipolar
disorder, and should be accounted for.
Conclusions
Literature on the role of neuroactive steroids in mental
disorders is sparse. Nonetheless we have made an at-
tempt to present a narrative review of existing studies
on neurosteroids acting on the GABAergic receptors.
Current evidence suggests that the investigation of neu-
roactive steroids on mental disorders might open new
frontiers in the investigation of the etiology and treat-
ment of mood disorders, particularly bipolar disorder.
Neurosteroids might be an endogenous mood stabilizer
and the alteration of their functioning on a genetic or
biochemical level might be responsible for the display of
symptoms in individuals vulnerable to bipolar disorder.
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